• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Minocycline Effects on Intracerebral Hemorrhage-Induced Iron Overload in Aged Rats Basic Sciences
This study quantified brain iron levels after ICH with magnetic resonance imaging R2* mapping. The effect of minocycline on iron overload and ICH-induced brain injury in aged rats was also determined.Methods—Aged (18 months old) male Fischer 344 rats had an intracerebral injection of autologous blood or saline, and brain iron levels were measured by magnetic resonance imaging R2* mapping. Some ICH rats were treated with minocycline or vehicle. The rats were euthanized at days 7 and 28 after ICH, and brains were used for immunohistochemistry and Western blot analyses. Magnetic resonance imaging (T2-weighted, T2* gradient-...
Source: Stroke - March 26, 2018 Category: Neurology Authors: Shenglong Cao, Ya Hua, Richard F. Keep, Neeraj Chaudhary, Guohua Xi Tags: Basic Science Research, Intracranial Hemorrhage Original Contributions Source Type: research

Letter by Chang et al Regarding Article, “Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial” Letter to the Editor
Source: Stroke - December 22, 2017 Category: Neurology Authors: Jason J. Chang, Nerses Sanossian, Georgios Tsivgoulis Tags: Biomarkers, Intracranial Hemorrhage, Neuroprotectants Letters to the Editor Source Type: research

Response by Fouda and Switzer to Letter Regarding Article, “Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial” Letter to the Editor
Source: Stroke - December 22, 2017 Category: Neurology Authors: Abdelrahman Y. Fouda, Jeffrey A. Switzer, MACH Investigators Tags: Intracranial Hemorrhage, Neuroprotectants Letters to the Editor Source Type: research

Minocycline in Acute Cerebral Hemorrhage Brief Report
Conclusions—In intracerebral hemorrhage, a 400 mg dose of minocycline was safe and achieved neuroprotective serum concentrations. However, oral administration led to delayed absorption in these critically ill patients and should not be used when rapid, high concentrations are desired. Given the safety and pharmacokinetic profile of minocycline in intracerebral hemorrhage and promising data in the treatment of ischemic stroke, intravenous minocycline is an excellent candidate for a prehospital treatment trial.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01805895.
Source: Stroke - September 25, 2017 Category: Neurology Authors: Abdelrahman Y. Fouda, Andrea S. Newsome, Samantha Spellicy, Jennifer L. Waller, Wenbo Zhi, David C. Hess, Adviye Ergul, David J. Edwards, Susan C. Fagan, Jeffrey A. Switzer Tags: Intracranial Hemorrhage, Neuroprotectants Brief Reports Source Type: research

Minocycline Reduces Spontaneous Hemorrhage in Mouse Models of Cerebral Amyloid Angiopathy Basic Sciences
Conclusions— Minocycline reduced gliosis, inflammatory gene expression, gelatinase activity, and spontaneous hemorrhage in 2 different mouse models of CAA, supporting the importance of matrix metalloproteinase–related and inflammatory pathways in intracerebral hemorrhage pathogenesis. As a Food and Drug Administration–approved drug, minocycline might be considered for clinical trials to test efficacy in preventing CAA-related intracerebral hemorrhage.
Source: Stroke - May 22, 2015 Category: Neurology Authors: Yan, P., Zhu, A., Liao, F., Xiao, Q., Kraft, A. W., Gonzales, E., Perez, R., Greenberg, S. M., Holtzman, D. M., Lee, J.-M. Tags: Animal models of human disease, Intracerebral Hemorrhage, Neuroprotectors Basic Sciences Source Type: research

Intravenous Minocycline in Acute Stroke: A Randomized, Controlled Pilot Study and Meta-analysis Clinical Sciences
Conclusions— In this pilot study of a small sample of acute stroke patients, intravenous minocycline was safe but not efficacious. The study was not powered to identify reliably or exclude a modest but clinically important treatment effect of minocycline. Larger trials would improve the precision of the estimates of any treatment effect of minocycline. Clinical Trial Registration— URL: http://www.anzctr.org.au. Unique identifier: ACTRN12612000237886.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Kohler, E., Prentice, D. A., Bates, T. R., Hankey, G. J., Claxton, A., van Heerden, J., Blacker, D. Tags: Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Neuroprotectors, Other Stroke Treatment - Medical Clinical Sciences Source Type: research

Monitoring Neuroprotective Effects Using Positron Emission Tomography With 11CITMM, a Radiotracer for Metabotropic Glutamate 1 Receptor Basic Sciences
Conclusions— [11C]ITMM-PET may be a useful technique for characterizing the change in mGlu1 level during the occurrence and progression of neuronal damage and for evaluating the neuroprotective effects of drugs after ischemia.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Yui, J., Xie, L., Fujinaga, M., Yamasaki, T., Hatori, A., Kumata, K., Nengaki, N., Zhang, M.-R. Tags: PET and SPECT Basic Sciences Source Type: research

Effects of Minocycline Plus Tissue Plasminogen Activator Combination Therapy After Focal Embolic Stroke in Type 1 Diabetic Rats Basic Sciences
Conclusions— Combination therapy with minocycline plus tPA may be beneficial in ameliorating inflammation and reducing infarction, brain swelling, and hemorrhage after ischemic stroke with diabetes mellitus/hyperglycemia.
Source: Stroke - February 25, 2013 Category: Neurology Authors: Fan, X., Lo, E. H., Wang, X. Tags: Animal models of human disease, Type 1 diabetes, Acute Cerebral Infarction, Embolic stroke, Thrombolysis Basic Sciences Source Type: research